The buyout was led by managing director Steve Brown, who will now serve as group CEO of the Redditch-headquartered company.
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter ...
On track to submit NDA in the second half of 2024 for Tonmya for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a pot ...